|
|
|
|
| LEADER |
02694nam a22003495i 4500 |
| 001 |
978-0-306-47384-5 |
| 005 |
20190617131255.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s1998 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9780306473845
|
| 024 |
7 |
|
|a 10.1007/b114429
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Integration of Pharmaceutical Discovery and Development
|b Case Histories /
|c edited by Ronald T. Borchardt, Roger M. Freidinger, Tomi K. Sawyer, Philip L. Smith.
|
| 250 |
|
|
|a 1st ed. 1998.
|
| 260 |
# |
# |
|a New York, NY :
|b Springer US :
|b Imprint: Springer,
|c 1998.
|
| 300 |
|
|
|a XXIX, 610 p. 31 illus., 1 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Pharmaceutical Biotechnology,
|v 11
|
| 505 |
0 |
|
|a Renin Inhibitors -- The Discovery and Development of Angiotensin II Antagonists -- Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor -- Discovery and Development of an Endothelin a Receptor-Selective Antagonist PD 156707 -- Endothelin Receptor Antagonists -- LHRH Antagonists -- LHRH Agonists -- Discovery and Development of Somatostatin Agonists -- Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors -- The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development -- De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule -- Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate -- Famciclovir -- The Use of Esters as Prodrugs for Oral Delivery of ?-Lactam Antibiotics -- Hematoregulators -- Discovery and Development of GG745, a Potent Inhibitor of Both Isozymes of of 5?-Reductase -- Discovery of a Potent and Selective ?1A Antagonist -- Discovery of Bioavailable Inhibitors of Secretory Phospholipase A2 -- The Anxieties of Drug Discovery and Development -- CI-1015 -- Orally Active Nonpeptide CCK-A Agonists -- Orally Active Growth Hormone Secretagogues -- Dorzolamide, a 40-Year Wait -- Discovery and Development of Novel Melanogenic Drugs.
|
| 650 |
|
0 |
|a Animal physiology.
|
| 650 |
|
0 |
|a Biochemistry.
|
| 650 |
1 |
4 |
|a Animal Physiology.
|
| 650 |
2 |
4 |
|a Biochemistry, general.
|
| 700 |
1 |
|
|a Borchardt, Ronald T.
|e editor.
|
| 700 |
1 |
|
|a Freidinger, Roger M.
|e editor.
|
| 700 |
1 |
|
|a Sawyer, Tomi K.
|e editor.
|
| 700 |
1 |
|
|a Smith, Philip L.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/b114429
|